Phenotypes Associated with This Genotype

Genotype
MGI:5902129

• Allelic Composition: Braf^tm1Mmcm/Braf⁺; Pten^tm2.1Ppp/Pten^tm2.1Ppp; Tg(Tyr-cre/ERT2)13Bos/0
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * FVB

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

integument

increased cutaneous melanoma incidence ( J:151023 )

• 7-10 days following 4-hydroxytamoxifen (4-HT) treatment, all mice show expansion of highly pigmented cells that develop into pigmented malignant lesions in locations of 4-HT administration such as the face, flank, or tail skin

• pigmented melanoma cells are seen throughout the dermis and subcutis of 4-HT treated mice and show pagetoid spread into the epidermis

• lesions in 4-HT treated mice progress rapidly to advanced malignancy such that all mice require euthanasia 25-50 days following 4-HT administration

• treatment of 4-HT treated mice with the MEK1/2 inhibitor PD325901 or the mTorc1 inhibitor rapamycin inhibits melanoma formation

• mice in which drug treatment is ceased subsequently develop malignant melanoma

• mice treated once with PD325901 to prevent melanoma remain sensitive to the anti-melanoma action of a second round of PD325901 administration

neoplasm

increased cutaneous melanoma incidence ( J:151023 )

• 7-10 days following 4-hydroxytamoxifen (4-HT) treatment, all mice show expansion of highly pigmented cells that develop into pigmented malignant lesions in locations of 4-HT administration such as the face, flank, or tail skin

• pigmented melanoma cells are seen throughout the dermis and subcutis of 4-HT treated mice and show pagetoid spread into the epidermis

• lesions in 4-HT treated mice progress rapidly to advanced malignancy such that all mice require euthanasia 25-50 days following 4-HT administration

• treatment of 4-HT treated mice with the MEK1/2 inhibitor PD325901 or the mTorc1 inhibitor rapamycin inhibits melanoma formation

• mice in which drug treatment is ceased subsequently develop malignant melanoma

• mice treated once with PD325901 to prevent melanoma remain sensitive to the anti-melanoma action of a second round of PD325901 administration

increased metastatic potential ( J:151023 )

• spread of melanoma in 4-HT treated mice is seen into the regional draining lymph nodes in 100% of mice and to the lungs in some cases

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
skin melanoma		DOID:8923	OMIM:608035 OMIM:612263	J:151023